Study of SYN818 with olaparib for advanced solid tumors
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor (like ovarian or HER2-negative breast cancer) with a BRCA mutation or similar DNA repair problem.
- You must have tried all standard treatments that are available to you.
- You must have at least one tumor that can be measured on scans.
- You must be generally healthy enough for treatment, with good organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYN608 for people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. It looks for a specific genetic change (BRCA mutation or related DNA repair problem) to see if the drug might work better for you.
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.